ArticleOphthalmology2024

Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a multicenter study (Ophthalmology. 2024;131:458-467).

Terry J SmithPubMed ↗Publisher ↗

No numbers read from the abstract.